Antibody drug conjugate (ADC)

Antibody drug conjugate
#Antibody drug conjugate (ADC) #In vitro #In vivo

Navigating considerations for ADCs: Guidance for the industry

This paid-for advertorial from Eurofins appeared in DDW Volume 26 – Issue 4, Fall 2025   Antibody-drug conjugates (ADCs) are increasingly promising due to advances in biologics and chemistry. With 16 FDA-approved ADCs, clinical interest is growing, though development remains complex, requiring thorough evaluation of the antibody, linker, payload, and… Read More

#Exclusive Content

eBook: The impact of ADCs on drug discovery
#Antibody drug conjugate (ADC) #Drug discovery #eBook #Therapeutic Antibodies

The impact of ADCs on drug discovery

This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates.

#DDW eBooks #Intelligence

Molecular,Model,Of,Antibody
#Antibody drug conjugate (ADC) #Biotechnology

Synaffix and Qurient Therapeutics reach agreement to develop ADCs

Biotechnology company Synaffix has announced it has entered a licensing agreement with biopharmaceutical company Qurient Therapeutics for the development of a dual-payload antibody-drug conjugates (ADCs).  Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and… Read More

#Business & Investment #News

Vaccine
#AI #Antibody drug conjugate (ADC) #Biopharma #Drug discovery #Vaccines

DDW Fall issue out now

The DDW Fall issue is out now and examines why there is a need for a universal pneumococcal vaccine, why China might be the next global biopharma powerhouse and looks at developments in microbiome research and the therapeutic sectors it is driving. It also features an exclusive guide exploring… Read More

#News

Scientist working with multi well plate for cell culture in the lab
#Antibody drug conjugate (ADC) #Drug discovery #GPCRs #Reagents #Revvity

Revvity launches new reagents for GPCR research

Revvity has launched pHSense reagents, designed to advance internalisation studies in drug discovery.   pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs).  Developed for use with standard plate readers, pHSense reagents combine a… Read More

#News

#AbbVie #Antibody drug conjugate (ADC) #MHRA #Oncology #Ovarian cancer

Elahere gets UK approval in platinum-resistant ovarian cancer

Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment… Read More

#News #Regulatory

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was approved under accelerated approval based… Read More

#News #Regulatory #Trending News

Antibodies
#Antibody drug conjugate (ADC) #Antibody-dependent cellular cytotoxicity #Case study #Drug discovery #Flow Cytometry

Case Study: ADC synthesis, development, and characterisation

A new Case Study is now available from Eurofins Discovery entitled ‘Synthesis & characterization of trastuzumab-based ADCs using fluorescent & cytotoxic payloads‘. Delve into these case studies on ADC synthesis, development, and characterisation, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow… Read More

#News

#Antibody drug conjugate (ADC) #Antibody-dependent cellular cytotoxicity #Drug discovery #Flow Cytometry

Synthesis & characterisation of trastuzumab-based ADCs using fluorescent & cytotoxic payloads

Delve into these case studies on ADC synthesis, development, and characterisation, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow cytometry and internalisation assays confirmed antigen targeting and cellular uptake. Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy… Read More

#Resources

#Antibody drug conjugate (ADC) #Sponsored content

Next-gen tools for next-gen therapies: Innovating ADC analysis

This article is sponsored by Phenomenex. As antibody-drug conjugates (ADCs) continue to emerge as a pivotal approach in targeted cancer therapeutics, the demand for precise and efficient characterisation methods is increasing. Determining the average drug-to-antibody ratio (DAR) is a key quality attribute for ADCs and conventional analysis via Hydrophobic Interaction… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Cancer research #Solid tumours #SOTIO

The challenges in solid tumour targeting with bispecific ADCs

Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More

#Cancer Research #Exclusive Content

Antibody drug conjugate
#AACR #Antibody drug conjugate (ADC) #Oncology #Solid tumours #SOTIO

ADCs show best-in-class potential for treating solid tumours

SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models.  The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Bispecific therapeutics #Checkpoint inhibitor therapies #Immune system #Immune therapy

Immune therapy – harnessing the host response

Dr Helen Bright FRSM, Chief Scientific Officer, Centauri Therapeutics discusses the intricacies of the body’s natural immune defences and explores how cutting-edge research is seeking to exploit it in order to drive development of a broad spectrum of innovative new immunotherapeutic technologies. The body's natural immune defences, whether in response… Read More

#Exclusive Content

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Genmab #Japan #Oncology

First ADC approved for cervical cancer in Japan

The Japan Ministry of Health, Labour and Welfare has approved Genmab’s Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after chemotherapy treatment.   Tivdak is the first antibody-drug conjugate (ADC) to be approved for people living with cervical cancer in Japan.  In… Read More

#News #Regulatory

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Drivers and challenges in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News